Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Tazi (Paris, France), F. Jouenne (Paris, France), E. Bugnet (Paris, France), G. Lorillon (Paris, France), V. Meignin (Paris, France), A. Sadoux (Paris, France), S. Chevret (Paris, France), S. Mourah (Paris, France). Clinical impact of BRAFV600E mutation in adult pulmonary Langerhans cell histiocytosis. 2141

Member's Comments

No comment yet.

Related content which might interest you: Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis Source: Eur Respir J 2016; 47:1785-1796 Year: 2016 Genetic landscape of adult Langerhans cell histiocytosis with lung involvement Source: Eur Respir J, 55 (2) 1901190; 10.1183/13993003.01190-2019 Year: 2020 Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 BRAF and NRAS mutations in circulating Langerhans-like CD1a+ cells in a patient with pulmonary Langerhans’ cell histiocytosis Source: Eur Respir J, 50 (4) 1700521; 10.1183/13993003.00521-2017 Year: 2017 Genetic landscape of pulmonary langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018 Lung function progression in Langerhans cell histiocytosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Chemotherapy in patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018 Paediatric pulmonary Langerhans cell histiocytosis Source: Breathe, 16 (2) 200003; 10.1183/20734735.0003-2020 Year: 2020 Pulmonary Langerhans' cell histiocytosis Source: Respipedia Article Year: 2016 How I manage pulmonary Langerhans cell histiocytosis Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017 Year: 2017 Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Pulmonary Langerhans cell histiocytosis Source: Annual Congress 2008 - PG5 - Interstitial lung diseases: selected orphan diseases Year: 2008 Pulmonary Langerhans‘ cell histiocytosis Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006 A role for ITPA variants in the clinical course of pulmonary Langerhans' cell histiocytosis? Source: Eur Respir J 2010; 36: 684-686 Year: 2010 Pulmonary Langerhans' cell histiocytosis Source: Eur Respir Mon; 2009: 46: 155–175 Year: 2009 Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 6 (2) 00230-2019; 10.1183/23120541.00230-2019 Year: 2020 Langerhans cell histiocytosis: is it an ILD? Source: Virtual Congress 2021 – Interstitial lung diseases Year: 2021 Lung transplantation for pulmonary Langerhans‘ cell histiocytosis Source: Eur Respir J 2005; 26: Suppl. 49, 635s Year: 2005 Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017 Year: 2018